Fundamentals are great and these announcements are positive but when is the revenue coming in that's the question. They're low on cash again and without getting lucky by winning that grant mentioned in the quarterly they'll need to raise again by the end of the year??
Punters lost patience with these kinds of loss-making biotech companies after the money printers were turned off and I don't think the interest has really returned yet. Punters in this end are usually speculating with some 'spare cash' but that spare cash has dried up imo.
We know if TGA approves the cannabis drug Aspen probably sell $100m p.a. and EMD receives $10m covering their annual capex but that's all yet to be confirmed. Obviously these stock prices for a company that's very likely to be profitable (if the above occurs) is a laugh but that's the share market.
Add to My Watchlist
What is My Watchlist?
